LOXL3 and melanoma: We have exposed a novel LOXL3–SNAIL1–PRRX1 axis relevant to melanoma phenotype switching, the targeting of which might represent an opportunity to combat resistance to targeted and immune-based therapies, a remaining challenge in the clinical management of melanoma.